Bioptik Technology (ROCO:4161) Issuance of Debt: NT$595.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4161 Bioptik Technology Inc ROCO:4161
71 GF Score
Price NT$22.80
GF Value NT$29.77
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Bioptik Technology Issuance of Debt?

Bioptik Technology ROCO:4161 +0.44% 71 Issuance of Debt is NT$595.0 Mil as of Jun. 2026. GuruFocus rates ROCO:4161 with a GF Score™ of 71/100 and a GF Value™ of NT$29.77 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Bioptik Technology's Issuance of Debt for the three months ended in Jun. 2026 was NT$190.0 Mil.

Bioptik Technology's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was NT$595.0 Mil.

Bioptik Technology Issuance of Debt Related Terms

Bioptik Technology Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Bioptik Technology's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioptik Technology Issuance of Debt Chart

Bioptik Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 610.00 990.00 1,082.00 690.00 645.00

Bioptik Technology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 245.00 40.00 240.00 125.00 190.00
ROCO:4161
71GF Score
Bioptik Technology Inc ROCO:4161
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioptik Technology Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$595.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of NT$595.0 Mil mean?
Bioptik Technology (ROCO:4161) has a Issuance of Debt of NT$595.0 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Bioptik Technology and its competitors.
Is Bioptik Technology's Issuance of Debt too high?
Bioptik Technology's current Issuance of Debt is NT$595.0 Mil. Overall, Bioptik Technology has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's Issuance of Debt compare to ABT and SYK?
Bioptik Technology's Issuance of Debt of NT$595.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Devices & Instruments company?
A good Issuance of Debt depends on the Medical Devices & Instruments industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Bioptik Technology and its competitors. Bioptik Technology's current Issuance of Debt is NT$595.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.77, compared to a current price of NT$22.80 — trading 23.4% below its estimated fair value. The current Issuance of Debt is NT$595.0 Mil. Bioptik Technology's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current Issuance of Debt is NT$595.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioptik Technology (ROCO:4161) Overvalued in 2026?

Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued. The current stock price of NT$22.80 is trading 23.4% below its estimated GF Value™ of NT$29.77. GuruFocus considers Bioptik Technology to be Modestly Undervalued.

Key valuation signals for ROCO:4161:

  • Issuance of Debt: NT$595.0 Mil
  • GF Value™: NT$29.77 vs. price of NT$22.80 (23.4% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioptik Technology Business Description

Address No.188, Zhonghua South Road, Miaoli County, Zhunan, TWN, 35057
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
71GF Score

Get the complete analysis for ROCO:4161

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.80
Price
NT$29.77
GF Value